Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

On December 12, 2023, Aditxt, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Current Report”) disclosing that on December 11, 2023, the Company entered into an Agreement and Plan of Merger (the “Original Agreement”) with Adifem, Inc. f/k/a Adicure, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”) and Evofem Biosciences, Inc., a Delaware corporation (“Evofem”), pursuant to which, Merger Sub will be merged into and with Evofem (the “Merger”), with Evofem surviving the Merger as a wholly owned subsidiary of the Company. On July 18, 2024, the Company filed a Current Report on Form 8-K (the “July Current Report” and together with the Original Current Report, the “Current Reports”) disclosing that on July 12, 2024, the Company, Merger Sub and Evofem entered in an Amended and Restated Merger Agreement (the “Merger Agreement”, which amended and restated the Original Agreement. On March 22, 2025, Evofem, Aditxt and Merger Sub entered into the Fifth Amendment to the Amended and Restated Merger Agreement (the “Fifth Amendment”) to change the required consummation date to September 30, 2025 and add an additional $1.5 million parent investment from Aditxt to Evofem in April 2025 which will be part of the overall consideration upon closing.

On August 1, 2024, the Company filed the first amendment to the Original Current Report (“Amendment No. 1”), which amended the Current Reports to include the required historical consolidated financial statements of Evofem as of and for the years ended December 31, 2023 and December 31, 2022 and the condensed consolidated financial statements as of and for the three months ended March 31, 2024, and the pro forma consolidated financial information as of and for the three months ended March 31, 2024 required by Items 9.01(a) and 9.01(b) of Form 8-K and should be read in conjunction with the Current Reports.

On September 5, 2024, the Company filed the second amendment to the Original Current Report (“Amendment No. 2”), which amended the Current Reports to include the required historical condensed consolidated financial statements of Evofem as of and for the six months ended June 30, 2024 and the pro forma consolidated financial information as of and for the six months ended June 30, 2024 required by Items 9.01(a) and 9.01(b) of Form 8-K and should be read in conjunction with the Current Reports.

On November 21, 2024, the Company filed the third amendment to the Original Current Report (“Amendment No. 3”), amends the Current Reports to include the required historical condensed consolidated financial statements of Evofem as of and for the nine months ended September 30, 2024 and the pro forma consolidated financial information as of and for the nine months ended September 30, 2024 required by Items 9.01(a) and 9.01(b) of Form 8-K and should be read in conjunction with the Current Reports.

On March 24, 2025, the Company filed the fourth amendment to the Original Current Report (“Amendment No. 4”), amends the Current Reports to include the required audited consolidated historical financial statements as of and for December 31, 2024 and 2023 of Evofem and the pro forma consolidated financial information as of and for the twelve months ended December 31, 2024 and 2023, required by Items 9.01(a) and 9.01(b) of Form 8-K and should be read in conjunction with the Current Reports.

As reported in a Current Report on Form 8-K filed by the Company, on May 19, 2025, the Company provided notice to Appili Therapeutics, Inc. (“Appili”) that it was terminating that certain Arrangement Agreement by and between the Company, Adivir, Inc., and Appili dated April 1, 2024 (the “Arrangement Agreement”) effective as of May 31, 2025. Accordingly, Appili has been removed from the unaudited pro forma condensed combined financial information of the Company as of and for the three months ended March 31, 2025 and 2024 contained in Exhibit 99.2 attached hereto.

This fifth amendment to the Original Current Report (“Amendment No. 5”), amends the Current Reports to include the required historical condensed consolidated financial statements of Evofem as of and for the three months ended March 31, 2025 and the pro forma consolidated financial information as of and for the three months ended March 31, 2025 required by Items 9.01(a) and 9.01(b) of Form 8-K and should be read in conjunction with the Current Reports. The pro forma consolidated financial information included as Exhibit 99.2 to this Current Report on Form 8-K/A has been presented for informational purposes only, as required by Form 8-K, and does not purport to represent the actual results of operations that the Company and Evofem would have achieved had the entities been combined at and during the period presented in the pro forma consolidated financial information, and is not intended to project the future results of operations that the combined company may achieve following the transactions.

This Amendment No. 5 does not amend any other item of the Original Current Report or purport to provide an update or a discussion of any developments at the Company or its subsidiaries subsequent to the filing date of the Original Current Report.

The unaudited condensed consolidated balance sheets of Evofem and subsidiaries as of March 31, 2025, and the related unaudited condensed consolidated statements of operations, comprehensive income (loss), convertible and redeemable preferred stock and stockholders’ deficit, and cash flows, for each of the three months ended March 31, 2025 and March 31, 2024, respectively, are filed as Exhibit 99.2 hereto and are incorporated herein by reference.

The unaudited pro forma condensed combined financial information of the Company giving pro forma effect to the acquisition of Evofem, consisting of the (i) unaudited pro forma consolidated statement of financial position as at March 31, 2025 and (ii) unaudited pro forma consolidated statement of operations for the three months ended March 31, 2025, are filed as Exhibit 99.3.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Delaware		001-39336		82-3204328
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2569 Wyandotte St., Suite 101, Mountain View, CA		94043
(Address of principal executive offices)		(Zip Code)

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		ADTX		The Nasdaq Stock Market LLC

Exhibit No.		Exhibit
99.1		Unaudited financial statements of Evofem Biosciences, Inc. and Subsidiaries as of March 31, 2025 and for the three months ended March 31, 2025 and 2024
99.2		Unaudited pro forma consolidated financial statements as of and for the three months ended March 31, 2025
104		Cover Page Interactive Data File (embedded within the XBRL document)

	ADITXT, INC.

Date: May 19, 2025	By:	/s/ Amro Albanna
		Amro Albanna
		Chief Executive Officer